PPI inhibits hepatocellular carcinoma (HCC) growth by inducing ferroptosis through the modulation of the Nrf2/HO-1/GPX4 antioxidant axis and causing mitochondrial dysfunction, with effects comparable to those of sorafenib. Here, NFE2L2 is linked to hepatocellular carcinoma.